Expression of DDX5 and DDX17 in ovarian cancer tissues and their effects on proliferation and drug resistance of human ovarian cancer cell line SKOV3

doi:10.16352/j.issn.1001-6325.2023.08.1247

Abstract

Abstract: Objective To analyze the expression of DDX5 and DDX17 in ovarian cancer and their relationship with patient survival, and to study the effects of DDX5 and DDX17 on proliferation and drug resistance of ovarian cancer cell line SKOV3. Methods The expression of DDX5 and DDX17 was detected by RT-qPCR in tissue samples from 40 cases of ovarian carcinoma and 27 controls. TCGA database was used to analyze the relationship between DDX15/DDX17 and survival prognosis of ovarian cancer patients. The expression of DDX5 and DDX17 in SKOV3 was down-regulated by lentivirus-mediated DDX5-shRNA and DDX17-shRNA. Western blot was used to verify the knockdown effect, and CCK8 was used to detect cell proliferation and resistance to paclitaxel and carboplatin. Results Compared with normal ovarian epithelium, the expression of DDX5 in samples from ovarian carcinoma was increased, while that of DDX17 was decreased significantly(P＜0.05); Ovarian cancer patients with high DDX5 expression had shorter progression-free survival and overall survival time, while those with high DDX17 expression had longer progression-free survival and overall survival time. Down-regulated DDX5 expression inhibited the SKOV3 cells proliferation, while down-regulated DDX17 expression promoted SKOV3 cells proliferation. The drug sensitivity of SKOV3 cells to paclitaxel and carboplatin was significantly increased after the down-regulation of DDX5 expression, while the drug sensitivity of SKOV3 cells to paclitaxel and carboplatin was not significantly changed after the down-regulation of DDX17 expression. Conclusions DDX5 and DDX17 regulate proliferation and drug resistance of ovarian cancer cells, and are potential regulatory factors functioning in ovarian cancer.

Key words: ovarian cancer, DDX5, DDX17, proliferation, drug resistance

CLC Number:

HUANG Jie, LI Runbo, GUO Jianxin, HAN Jian. Expression of DDX5 and DDX17 in ovarian cancer tissues and their effects on proliferation and drug resistance of human ovarian cancer cell line SKOV3[J]. Basic & Clinical Medicine, 2023, 43(8): 1247-1253.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal11.magtechjournal.com/Jwk_jcyxylc/EN/10.16352/j.issn.1001-6325.2023.08.1247

http://journal11.magtechjournal.com/Jwk_jcyxylc/EN/Y2023/V43/I8/1247

References

[1]Wang Z, Guo E, Yang B, et al. Trends and age-period-cohort effects on mortality of the three major gynecologic cancers in China from 1990 to 2019: Cervical, ovarian and uterine cancer[J]. Gynecol Oncol, 2021, 163:358-363.
[2]Zheng R, Zhang S, Zeng H, et al. Cancer incidence and mortality in China, 2016[J]. J Natl Cancer Cent, 2022, 1:1-9.
[3]Ali MAM. DEAD-box RNA helicases: The driving forces behind RNA metabolism at the crossroad of viral replication and antiviral innate immunity[J]. Virus Res, 2021, 296:198352. doi: 10.1016/j.virusres.2021.198352.
[4]Nyamao RM, Wu J, Yu L, et al. Roles of DDX5 in the tumorigenesis, proliferation, differentiation, metastasis and pathway regulation of human malignancies[J]. Biochim Biophys Acta Rev Cancer, 2019, 1871:85-98.
[5]Xue Y, Jia X, Li C, et al. DDX17 promotes hepatocellular carcinoma progression via inhibiting Klf4 transcriptional activity[J]. Cell Death Dis, 2019, 10:814-825.
[6]Wu KJ. The role of miRNA biogenesis and DDX17 in tumorigenesis and cancer stemness[J]. Biomed J, 2020, 43:107-114.
[7]姚莎莎,尚文雯,徐睿,等. 沉默PDK1基因抑制卵巢癌细胞系SKOV3的增殖及侵袭[J]. 基础医学与临床, 2019, 39: 1381-1387.
[8]Wills B, Fan Q, Alexander C, et al. Confusion following treatment of ovarian cancer[J]. Am J Med, 2019, 132: e610-e611.
[9]Luo Q, Que T, Luo H, et al. Upregulation of DEAD box helicase 5 and 17 are correlated with the progression and poor prognosis in gliomas[J]. Pathol Res Pract, 2020, 216:152828. doi: 10.1016/j.prp.2020.152828.
[10]郭菲菲,康岚. Ddx5和Ddx17在肿瘤中的表达调控及意义[J]. 中国科技论文在线精品论文, 2018, 11:862-870.
[11]Zhou HZ, Li F, Cheng ST, et al. DDX17-regulated alternative splicing that produced an oncogenic isoform of PXN-AS1 to promote HCC metastasis[J]. Hepatology, 2022, 75:847-865.
[12]Wortham NC, Ahamed E, Nicol SM, et al. The DEAD-box protein p72 regulates ERalpha-/oestrogen-dependent transcription and cell growth, and is associated with improved survival in ERalpha-positive breast cancer[J]. Oncogene, 2009, 28:4053-4064.
[13]Giraud G, Terrone S, Bourgeois CF. Functions of DEAD box RNA helicases DDX5 and DDX17 in chromatin organization and transcriptional regulation[J]. BMB Rep, 2018, 51:613-622.
[14]Cui Y, Hunt A, Li Z, et al. Lead DEAD/H box helicase biomarkers with the therapeutic potential identified by integrated bioinformatic approaches in lung cancer[J]. Comput Struct Biotechnol J, 2020, 19:261-278.
[15]Zhang L, Li X. DEAD-box RNA helicases in cell cycle control and clinical therapy[J]. Cells, 2021, 10:1540-1560.
[16]Xu K, Sun S, Yan M, et al. DDX5 and DDX17-multifaceted proteins in the regulation of tumorigenesis and tumor progression[J]. Front Oncol, 2022, 12:943032.doi: 10.3389/fonc.2022.943032.